Effectiveness of acceptance and commitment therapy for panic disorder patients who are resistant to cognitive behavioral therapy

Effectiveness of acceptance and commitment therapy for panic disorder patients who are resistant to cognitive behavioral therapy - Effectiveness of acceptance and commitment therapy for panic disorder patients who are resistant to cognitive behavioral therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028577

Enrollment

Registered

2017-08-09

Start date

2017-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder Agraphobia

Interventions

Group acceptance and commitment therapy: eight to ten weekly 90min to 120min sessions

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)Patient with principal diagnosis of DSM-5 Panic disorder and Agoraphobia 2)PDSS score =>8 at baseline 3)Patient who had completed group panic CBT program in Nagoya city university hospital. 4) Patinet who demnstrated less than 40% redaction of PDSS score and more than 6 of PDSS score at end of group panic CBT

Exclusion criteria

Exclusion criteria: 1 Requirement for hospitalization. 2 Severe depressive symptom to interfere with the understanding of treatment material. 3 Severe suicidal ideation. 4 Psychotic symptom at baseline. 5 Manic or hypomanic episode at baseline. 6 History of schizophrenia or bipolar I disorder. 7 Mental retardation, substance abuse, mental disorders caused by general physical diseases,dementia, personality disorder. 8 Receiving other structured psychotherapy,except supportive counseling. 9 Other relevant reason decided by the investigators.

Design outcomes

Primary

Measure	Time frame
PDSS (Panic Disorder Severity Scale) PDSS is evaluated at the end of therapy and 13 weeks after therapy.	—

Secondary

Measure	Time frame
BDI-2 (Beck Depression Inventory-2) AAQ-2(Acceptance and Action Questionnaire-2) FFMQ(Five Facet Mind-fullness Questionnaire) CFQ(Cognitive Fusion Questionnaire) ASI-3(Anxiety Sensitivity Index-3) SCL-90R(Symptom Check List 90 Revised) SF-36(MOS 36 Item Short-Form Health Survey) PDS(PTSD Diagnostic Scale) PSWQ(Penn-State Worry Questionnaire) FQ-A (Fear Questionnaire-agoraphobia subscale) MIA(The Mobility Inventory for Agoraphobia) ACQ(Agoraphobia Cognitive Questionnaire) BSQ(Body Sensation Questionnaire) AQ(Autism-Spectrum Quotient)	—

Measure

Time frame

BDI-2 (Beck Depression Inventory-2) AAQ-2(Acceptance and Action Questionnaire-2) FFMQ(Five Facet Mind-fullness Questionnaire) CFQ(Cognitive Fusion Questionnaire) ASI-3(Anxiety Sensitivity Index-3) SCL-90R(Symptom Check List 90 Revised) SF-36(MOS 36 Item Short-Form Health Survey) PDS(PTSD Diagnostic Scale) PSWQ(Penn-State Worry Questionnaire) FQ-A (Fear Questionnaire-agoraphobia subscale) MIA(The Mobility Inventory for Agoraphobia) ACQ(Agoraphobia Cognitive Questionnaire) BSQ(Body Sensation Questionnaire) AQ(Autism-Spectrum Quotient)

—

Countries

Japan

Contacts

Public ContactKEIKO INO

Nagoya City University Graduate School of Medical Sciences Department of Psychiatry and Cognitive Behavioral Medicine

keiko-ino@umin.ac.jp052-853-8271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026